Dagmar Galter

List of Publications by Year
in descending order

75 papers	5,988 citations	81839 39 h-index	79644 73 g-index
75 all docs	75 docs citations	75 times ranked	8436 citing authors

#	Article	IF	Citations
1	Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1325-1330.	3.3	516
2	PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell, 2004, 6, 333-345.	7.7	480
3	Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB Journal, 1994, 8, 1131-1138.	0.2	419
4	Modulation of the endoplasmic reticulumâ€“mitochondria interface in Alzheimerâ€™s disease and related models. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7916-7921.	3.3	381
5	Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 2011, 6, e18568.	1.1	338
6	Distinct effects of glutathione disulphide on the nuclear transcription factors kappaB and the activator protein-1. FEBS Journal, 1994, 221, 639-648.	0.2	253
7	PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nature Medicine, 2012, 18, 100-110.	15.2	185
8	Vascular Endothelial Growth Factor-A Promotes Peritumoral Lymphangiogenesis and Lymphatic Metastasis. Cancer Research, 2005, 65, 9261-9268.	0.4	170
9	LRRK2 expression linked to dopamine-innervated areas. Annals of Neurology, 2006, 59, 714-719.	2.8	166
10	Modulation of transcription factor NFÏ‡B activity by intracellular glutathione levels and by variations of the extracellular cysteine supply. FASEB Journal, 1995, 9, 246-252.	0.2	151
11	ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiology of Disease, 2003, 14, 637-647.	2.1	148
12	Growth/Differentiation Factor-15/Macrophage Inhibitory Cytokine-1 Is a Novel Trophic Factor for Midbrain Dopaminergic NeuronsIn Vivo. Journal of Neuroscience, 2000, 20, 8597-8603.	1.7	145
13	mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex. Nature Neuroscience, 2013, 16, 499-506.	7.1	130
14	Parkinsonâ€™s disease: genetic versus toxinâ€induced rodent models. FEBS Journal, 2008, 275, 1384-1391.	2.2	126
15	VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 389-394.	3.3	123
16	Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB Journal, 2011, 25, 1333-1344.	0.2	112
17	The MitoPark Mouse â€“ An animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism and Related Disorders, 2009, 15, S185-S188.	1.1	101
18	Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinsonâ€™s disease. Neuroscience, 2008, 152, 429-436.	1.1	96

#	Article	IF	Citations
19	MitoPark mice mirror the slow progression of key symptoms and Lâ€DOPA response in Parkinson's disease. Genes, Brain and Behavior, 2010, 9, 173-181.	1.1	92
20	Neurodegenerative phenotypes in an A53T Â-synuclein transgenic mouse model are independent of LRRK2. Human Molecular Genetics, 2012, 21, 2420-2431.	1.4	84
21	Sequential Activation of the 5-HT1A Serotonin Receptor and TrkB Induces the Serotonergic Neuronal Phenotype. Molecular and Cellular Neurosciences, 2000, 15, 446-455.	1.0	80
22	Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinsonâ€™s and Alzheimerâ€™s disease. Cell and Tissue Research, 2017, 369, 445-454.	1.5	79
23	Distribution of class I, III and IV alcohol dehydrogenase mRNAs in the adult rat, mouse and human brain. FEBS Journal, 2003, 270, 1316-1326.	0.2	78
24	Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neuroscience Letters, 2009, 452, 8-11.	1.0	73
25	Brain-derived neurotrophic factor and trkB are essential for cAMP-mediated induction of the serotonergic neuronal phenotype. Journal of Neuroscience Research, 2000, 61, 295-301.	1.3	65
26	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiology of Disease, 2014, 71, 345-358.	2.1	59
27	A Rare Truncating Mutation in ADH1C (G78Stop) Shows Significant Association With Parkinson Disease in a Large International Sample. Archives of Neurology, 2005, 62, 74.	4.9	57
28	Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Research, 2007, 1184, 10-16.	1.1	50
29	Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden. Neurobiology of Aging, 2016, 45, 212.e5-212.e11.	1.5	50
30	Role of cysteine and glutathione in signal transduction, immunopathology and cachexia. BioFactors, 1998, 8, 97-102.	2.6	48
31	Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Movement Disorders, 2006, 21, 1731-1734.	2.2	47
32	Transcriptomic profiling of the human brain reveals that altered synaptic gene expression is associated with chronological aging. Scientific Reports, 2017, 7, 16890.	1.6	47
33	S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. Parkinsonism and Related Disorders, 2007, 13, 295-298.	1.1	46
34	An organic electronic biomimetic neuron enables auto-regulated neuromodulation. Biosensors and Bioelectronics, 2015, 71, 359-364.	5.3	44
35	Role of Cysteine and Glutathione in HIV Infection and Cancer Cachexia: Therapeutic Intervention with N-Acetylcysteine. Advances in Pharmacology, 1996, 38, 581-600.	1.2	43
36	Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2007, 420, 257-262.	1.0	41

#	Article	IF	Citations
37	Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell and Tissue Research, 2008, 334, 179-185.	1.5	41
38	Age-associated mosaic respiratory chain deficiency causes trans-neuronal degeneration. Human Molecular Genetics, 2008, 17, 1418-1426.	1.4	41
39	Cerebellar Î±synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB Journal, 2008, 22, 3509-3514.	0.2	41
40	MAGI1 Copy Number Variation in Bipolar Affective Disorder and Schizophrenia. Biological Psychiatry, 2012, 71, 922-930.	0.7	41
41	Differential regulation of distinct phenotypic features of serotonergic neurons by bone morphogenetic proteins. European Journal of Neuroscience, 1999, 11, 2444-2452.	1.2	39
42	Tissue- and species-specific expression patterns of class I, III, and IV Adh and Aldh1 mRNAs in rodent embryos. Cell and Tissue Research, 2005, 322, 227-236.	1.5	38
43	Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 422-424.	1.1	38
44	NURR1promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits. , 2003, 120B, 51-57.		36
45	Lrrk2 and Î±-synuclein are co-regulated in rodent striatum. Molecular and Cellular Neurosciences, 2008, 39, 586-591.	1.0	36
46	Altered Expression of Growth Associated Proteinâ€43 and Rho Kinase in Human Patients with Parkinson's Disease. Brain Pathology, 2017, 27, 13-25.	2.1	35
47	Regulation of the transmitter phenotype of rostral and caudal groups of cultured serotonergic raphe neurons. Neuroscience, 1999, 88, 549-559.	1.1	34
48	Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in Sweden. Neuroscience Letters, 2010, 485, 117-120.	1.0	32
49	Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET Neuroimaging. Journal of Parkinson's Disease, 2014, 4, 483-498.	1.5	32
50	High and complementary expression patterns of alcohol and aldehyde dehydrogenases in the gastrointestinal tract. FEBS Journal, 2007, 274, 1212-1223.	2.2	30
51	Enhanced dendritogenesis and axogenesis in hippocampal neuroblasts of LRRK2 knockout mice. Brain Research, 2013, 1497, 85-100.	1.1	30
52	GDNF-related factor persephin is widely distributed throughout the nervous system. , 1998, 53, 494-501.		29
53	Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease. Neuroscience Letters, 2012, 522, 30-35.	1.0	27
54	Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiology of Disease, 2010, 40, 460-466.	2.1	25

#	Article	IF	Citations
55	Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease. FASEB Journal, 2011, 25, 1345-1352.	0.2	25
56	No Dopamine Cell Loss or Changes in Cytoskeleton Function in Transgenic Mice Expressing Physiological Levels of Wild Type or G2019S Mutant LRRK2 and in Human Fibroblasts. PLoS ONE, 2015, 10, e0118947.	1.1	24
57	Developmental regulation of the serotonergic transmitter phenotype in rostral and caudal raphe neurons by transforming growth factor-Î²s. Journal of Neuroscience Research, 1999, 56, 531-538.	1.3	21
58	DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents. Physiology and Behavior, 2007, 92, 46-53.	1.0	21
59	Nestin-like immunoreactivity of corpora amylacea in aged human brain. Molecular Brain Research, 2001, 94, 204-208.	2.5	20
60	Chronic Lâ€•DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice. Genes, Brain and Behavior, 2015, 14, 260-270.	1.1	19
61	Possible Involvement of a Mitochondrial Translation Initiation Factor 3 Variant Causing Decreased mRNA Levels in Parkinson's Disease. Parkinson's Disease, 2010, 2010, 1-5.	0.6	14
62	Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease. Behavioural Brain Research, 2012, 227, 252-257.	1.2	13
63	Modeling Parkinson's disease genetics: Altered function of the dopamine system in Adh4 knockout mice. Behavioural Brain Research, 2011, 217, 439-445.	1.2	12
64	Genetic Variations and mRNA Expression of NRF2 in Parkinsonâ€™s Disease. Parkinson's Disease, 2017, 2017, 1-7.	0.6	12
65	[23] Thiols and the immune system: Effect of N-acetylcysteine on T cell system in human subjects. Methods in Enzymology, 1995, 251, 255-270.	0.4	11
66	Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson's Disease. The Open Neurology Journal, 2012, 6, 1-5.	0.4	10
67	Genetic studies of the protein kinase AKT1 in Parkinson's disease. Neuroscience Letters, 2011, 501, 41-44.	1.0	9
68	Histamine induces KCNQ channel-dependent gamma oscillations in rat hippocampus via activation of the H1 receptor. Neuropharmacology, 2017, 118, 13-25.	2.0	7
69	Comparison of Three Hypothermic Target Temperatures for the Treatment of Hypoxic Ischemia: mRNA Level Responses of Eight Genes in the Piglet Brain. Translational Stroke Research, 2013, 4, 248-257.	2.3	6
70	ADAR2 affects mRNA coding sequence edits with only modest effects on gene expression or splicingin vivo. RNA Biology, 2016, 13, 15-24.	1.5	6
71	Procaine has opposite effects on passive Na and K permeabilities in frog skin. Pflugers Archiv European Journal of Physiology, 1987, 408, 215-219.	1.3	5
72	PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell, 2006, 9, 239.	7.7	2

#	Article	IF	Citations
73	Parkinson's Disease: recent progress. FEBS Journal, 2008, 275, 1369-1369.	2.2	1
74	Brainâ€derived neurotrophic factor and trkB are essential for cAMPâ€mediated induction of the serotonergic neuronal phenotype. Journal of Neuroscience Research, 2000, 61, 295-301.	1.3	1
75	S18Y, UCH-L1 and Parkinsonâ€™s Disease. European Neurological Review, 2008, 3, 41.	0.5	1